Isis Pharmaceuticals Inc., of Carlsbad, Calif., said phase II results of ISIS-APOCIII in patients with high triglycerides and type 2 diabetes show it achieved statistically significant average mean percent reduction from baseline of 88 percent (p = 0.02) in apolipoprotein C-III and 69 percent (p = 0.02) in triglycerides, and an average mean percent increase of 42 percent (p = 0.03) in high-density lipoprotein cholesterol after 13 weeks of dosing.